A REMS program of education and monitoring was developed for rapid-acting fentanyl commercial products in light of reports of rising fentanyl use outside of licensing guidelines and indications. Parenteral fentanyl went off patent in 1981 and sales thereafter skyrocketed 10-fold over the next 10 years ( 4). In 1990 transdermal fentanyl became available for opioid tolerant individuals and in the 1990’s and beginning in 1998 a series of rapid-acting transmucosal fentanyl products became commercially available for breakthrough pain ( 1- 3). In 1960 Janssen developed parenteral fentanyl which received FDA approval in 1968. Keywords: Fentanyl utility respiratory depression wooden chest syndrome substance abuse Policy of Dealing with Allegations of Research Misconduct.Policy of Screening for Plagiarism Process.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |